What a GLP-1 Plotter Actually Shows You (And What It Can't)

A GLP-1 plotter is a calculator that draws how much medication is in your system over time — the rise after each injection, the plateau as weekly doses stack, and the taper before the next shot. It takes three inputs: your dose, how often you take it, and the drug's half-life. Everything else on the screen is arithmetic.

That arithmetic is genuinely useful. It explains why week one of a new dose feels different from week six, why your appetite may drift back late in the week, and why stopping doesn't feel like anything for the first several days. But the curve is a model built on population averages, not a measurement of your blood. Understanding that distinction is the difference between a plotter being a good mental model and a bad decision-making tool.

What the curve is actually made of

Nearly every GLP-1 plotter you'll find — including Tiro's dosage plotter — runs some version of a one-compartment pharmacokinetic model. It treats your body as a single well-mixed container. Drug goes in through the injection, spreads instantly through the container, and leaves at a rate proportional to how much is there.

Two numbers drive the whole thing:

From the FDA prescribing information for each drug:

• Semaglutide (Ozempic, Wegovy) — elimination half-life of approximately 1 week, and detectable in circulation for about 5 weeks after the final dose.
• Tirzepatide (Mounjaro, Zepbound) — half-life of approximately 5 days, with concentrations peaking roughly 8 to 24 hours after each injection.

Both reach steady state after about 4 to 5 weeks of once-weekly dosing at the same dose. That single fact explains more about the GLP-1 experience than any other number in this article.

The three shapes worth recognising

1. The climb

When you start a dose — any dose, not just the first one — you are not at that dose's full effect yet. Each weekly injection lands on top of what's left from the previous one, and the total keeps rising for four to five weeks before it levels off.

This is why "the second month was harder than the first" is such a common report. You didn't change anything. The curve was still climbing.

2. The plateau

Once you're at steady state, each week looks like the last: a peak a day or so after the shot, a gentle decline, then the next injection catches it before it falls far. The week-to-week variation is small because the half-life is long relative to the dosing interval.

Semaglutide's longer half-life produces a shallower weekly trough than tirzepatide's. That's a real structural difference between the two molecules, and it's visible on the plot the moment you switch drugs in the tool.

3. The tail

When you stop, nothing happens for a while. With a one-week half-life, semaglutide is still at roughly half its steady-state level a week after the last dose, a quarter after two weeks. People often expect the effect to end when the injections do, and are surprised by the delay in both directions. If you're planning a stop, the shape of that tail is the whole story — see our guide to weaning off semaglutide.

Why two plotters give you two different numbers

If you've compared a few of these tools you'll have noticed they disagree, sometimes substantially. That's not a bug in one of them. The disagreements come from real modelling choices:

• Different half-life values. Published half-lives are ranges, not constants. Picking 6.5 days versus 7.5 days for semaglutide changes every downstream number.
• Absorption modelled or ignored. Simpler plotters assume the full dose appears instantly. Better ones model first-order absorption, which rounds off the peak and shifts it later.
• Units. Some plot milligrams "in system," some plot estimated plasma concentration, some plot an arbitrary 0–100 index. These are not comparable to each other at all.
• Bioavailability assumptions. How much of an injected dose actually reaches circulation is not 100%, and tools handle this differently — or not at all.

The practical rule: trust the shape, not the digits. Every credible plotter agrees that levels climb for four to five weeks, plateau, and decay slowly. None of them can tell you your actual serum concentration, and any tool presenting a number to two decimal places is implying a precision it does not have.

What a plotter cannot do

This is the section most tools leave out, so let's be direct about it.

It can't tell you your real blood level. The model uses population-average parameters. Your absorption, body composition, kidney function and injection technique all move the real curve away from the modelled one.

It can't tell you whether a dose is working. Drug exposure and clinical response are different things. Plenty of people do well at 5 mg and plateau at 10 mg. The curve knows nothing about your weight, appetite or blood sugar.

It can't tell you a dose is safe. Side-effect risk rises with dose, but the plot has no information about your medical history, your other medications, or the symptoms you're having this week.

It can't justify a dose change. This is the important one. Seeing a trough on a chart is not a clinical reason to increase, split or add a dose. Titration is a prescriber decision made against the approved dose ladder, and the labelled schedules exist because they were the ones tested in trials. If your curve prompts a question, the answer to that question comes from your prescriber, not from the tool.

Reading your own curve usefully

Where a plotter genuinely earns its place is in pattern-matching your own logged experience against the shape.

If you track your shots and symptoms, you can lay your real data over the modelled curve and see whether they line up. Some patterns that show up this way:

• Nausea clustering on the steep part of the rise, one to three days post-injection — the same window described in our guide to when side effects peak.
• Appetite drifting back in the last day or two before the next shot, at the bottom of the trough. Whether that's a genuine trough effect or the beginning of tolerance is the question we unpack in food noise coming back.
• A dose increase feeling fine for two weeks and harder in week three — the climb to the new steady state, not a new problem.

None of these are diagnoses. They're observations that make a better conversation with your prescriber than "it feels weird sometimes."

Plotters by drug

The curve differs by molecule, and the tool should too:

A note on retatrutide: it is an investigational compound that is not approved by the FDA, the MHRA or the EMA for any use. There is no licensed prescribing information and no approved dose ladder. Any plot of it is an extrapolation from early-phase research, and should be read with far more caution than a plot of an approved drug. We cover that in detail in the retatrutide dosing guide.

What the model leaves out

Every input a plotter doesn't ask you for is an assumption it's making.

Bioavailability by route. How much of a dose reaches circulation differs between a pen, a vial drawn into a syringe, and — for oral formulations — a tablet. Most plotters assume a single figure or ignore the question entirely. If you've moved between formats, the curve may not be comparing like with like. Our vial transition guide covers what actually changes.

Body size and composition. Volume of distribution scales with body size, so the same milligram dose produces different concentrations in different people. A plotter that asks only for dose and interval has silently assumed you're average.

Injection site and technique. Absorption varies slightly by site, and an incomplete injection delivers less than the dial says. See stomach, thigh or arm.

Adherence. The curve assumes you injected exactly on schedule. A dose taken two days late produces a real dip the model won't show unless you log it.

Everything clinical. Kidney function, other medications, and the conditions being treated are all absent from the maths.

None of these invalidate the tool. They define what it's for: understanding the shape of your dosing regimen, not estimating your serum concentration.

A worked example

Say you're moving from tirzepatide 5 mg to 7.5 mg, injecting Mondays.

• Monday, week 1. First 7.5 mg dose. Your system still holds residue from weeks of 5 mg, so the total is already above where 7.5 mg alone would put it. Concentration peaks 8–24 hours later, so Tuesday is the high point.
• Weeks 2–3. Each Monday adds to a rising baseline. The trough before each shot sits higher than the week before. This is usually where new side effects show up — not week one.
• Weeks 4–5. The rise flattens. Peaks and troughs stop climbing. This is your actual experience of 7.5 mg.
• Anything after. Stable, until the next change.

The practical read: judge a dose at week four or five, not week one. People routinely conclude a dose "isn't doing anything" during the climb, and conclude a dose is "too strong" at exactly the point it was always going to peak.

Where plotters get misused

Two patterns worth naming, because both show up constantly in online discussion.

Using a trough to justify splitting doses. A visible dip before the next injection looks like a problem the maths could solve — inject half as much, twice as often, flatten the line. The curve makes this look elegant. It is still off-label dose manipulation of a prescription medication, and the approved schedules are the ones that were actually tested. We cover the reasoning in splitting GLP-1 doses.

Treating the y-axis as a target. Some tools display a number that invites comparison — with your past self, or with someone else's screenshot. Since the units are arbitrary and the assumptions differ between tools, cross-comparison is meaningless. Your curve is only comparable with your own curve, from the same tool, with the same settings.

Frequently asked questions

What is a GLP-1 plotter? A calculator that estimates how much medication is in your system over time from your dose, interval and the drug's half-life, and draws it as a curve.

Is a GLP-1 plotter accurate? It's a model, not a measurement. It shows the shape of a typical curve using population-average pharmacokinetics, not your personal blood levels.

Why do two plotters give different numbers? Different half-life assumptions, different absorption models, different units and different bioavailability handling. The shape usually agrees even when the numbers don't.

How long until levels reach steady state? About 4 to 5 weeks of once-weekly dosing at the same dose, for both semaglutide and tirzepatide. Every increase restarts the climb.

What are the half-lives? Semaglutide approximately 1 week, present in circulation about 5 weeks after the last dose. Tirzepatide approximately 5 days.

Can a plotter tell me when to increase my dose? No. It shows exposure, not whether a dose is working or safe. That decision is your prescriber's.

See the curve your own shots actually make

Plot your levels → · Plan a titration step → · All Tiro GLP-1 tools →

Tiro is a tracker and companion app. It is not a treatment, does not diagnose, and does not replace your prescriber. Pharmacokinetic figures cited from FDA prescribing information for semaglutide and tirzepatide.